MAIA Biotechnology is advancing its lead immunotherapy candidate, ateganosine, through critical late-stage trials targeting advanced non-small cell lung cancer (NSCLC) patients resistant to standard treatments. The company expanded its Phase 2 THIO-101 trial with combination and monotherapy arms and initiated a pivotal Phase 3 trial directly comparing ateganosine-based therapy against chemotherapy. Collaborations with Regeneron and BeOne Medicines reduce clinical costs and provide access to checkpoint inhibitors essential for combination regimens. While promising efficacy signals support regulatory ambitions, MAIA faces typical biotech risks including clinical and regulatory uncertainties, patient enrollment challenges, capital needs, and pipeline concentration. Financially, the company holds a strong current ratio of approximately 4.5 with no reported debt as of mid-2026, supporting ongoing development efforts [S2][S1][F1].